Cibus Global has created two new positions to strengthen its scientific management team. Gail Hall will join the team as vice president for trait management, and Greg Gocal will be promoted to vice president, research.
“As Cibus continues to expand its trait development activities through a number of new global partnerships, we are strengthening our senior management team in R&D to properly position the organization for anticipated future growth,” says Peter Beetham, senior vice president of research, Cibus Global. “Trait development in plant genetics requires significant project management experience associated with strict timelines, and Gail brings a strong background in this field. In his 10 years with Cibus Global, Greg has been an integral part of building the Cibus team to its present position, and has become one of the world leaders in Rapid Trait Development System (RTDS) technology. We’re pleased to welcome them both to their new management roles.”
Gail Hall, Vice President for Trait Management
In her newly-created position, Hall will work closely with the management team on trait development for all of Cibus Global’s programs. Prior to joining Cibus Global, Ms. Hall’s experience included clinical, marketing and regulatory activities as a senior manager and project leader in a diverse range of global chemical and drug companies, including Alliance Pharmaceutical Corp., SONUS Pharmaceuticals Inc., and Mallinckrodt Medical Inc. Most recently, she held the post of vice president clinical affairs at IMCOR Pharmaceutical Co., where she facilitated product commercialization and expansion and improved client services.
Greg Gocal, Vice President, Research
Dr. Gocal rises to the new position of vice president, research, from his position as director, research. He will lead scientific activities to deliver on many of RTDSs new applications. Prior to joining Cibus, Dr. Gocal was the scientist leading the molecular biology group of the Plant and Industrial Products Division at ValiGen. Since joining Cibus he has held various research management positions primarily focused on developing the molecular aspects of the technology including target characterization, mutation discovery, molecular screening, and assay development. Dr. Gocal has been central in developing the RTDS technology in plant and microbial systems.
RTDS, Cibus’ proprietary gene conversion technology, enables seed producers to develop plants that are quicker to market with less regulatory expense. RTDS is a non-transgenic approach for providing plant improvements as compared to classical genetic transformation, a process leading to GM products. During the last 15 months, Cibus has successfully secured nearly $50 million in research contracts with partners to develop non-transgenic traits in crops around the world which has lead to a significant expansion of research and commercial based activities for Cibus Global.